<DOC>
	<DOC>NCT00458835</DOC>
	<brief_summary>The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI). The administration of the study medication will be as follows: three single doses, separated by a wash-out period. The study will provide further data on the safety and tolerability of ciclesonide.</brief_summary>
	<brief_title>Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written informed consent and HIPAA Body weight as indicate by a Body Mass Index (BMI) between ≥ 18 and ≤ 28 kg/m², and a body weight &gt;50 kg General good health Ability to use oral inhaler Main Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in premenopausal women Participation in any investigational drug trial within the 30 days before Screening Visit and thereafter History or current clinically relevant allergies or idiosyncrasy to drugs or food History of allergic reactions to any corticosteroids including ciclesonide or any excipients of the formulations Any contraindication to nasally administered corticosteroids History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 30 days before Screening Visit, or development of a respiratory infection during the Screening Period History or current evidence of any other relevant allergic, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, metabolic, neurological, psychiatric, or other disease within the last 2 years Nonvaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Allergic rhinitis</keyword>
</DOC>